Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Wu, Jieyu ^a   Lin, Yunen ^a   He, Xinming ^a   Yang, Haihong ^a   He, Ping ^a   Fu, Xinge ^a   Li, Guangqiu ^a   Gu, Xia ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Fluorescent in situ hybridization; Immunohistochemistry; Non small cell lung cancer; Quantitative real time polymerase chain reaction; ROS1; Tyrosine kinase inhibitors

Indexed keywords

CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; ROS1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ALK GENE; ARTICLE; CANCER GRADING; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; EGFR GENE; EXON; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE FUSION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; KRAS GENE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; ONCOGENE; PERIPHERAL EDEMA; PROTO ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; ROS1 GENE; SEQUENCE ANALYSIS; TUMOR CELL; VOMITING; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; GENETIC PROCEDURES; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; TISSUE MICROARRAY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; GENETIC TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE FUSION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS;

EID: 84984846908     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2582-9     Document Type: Article

References (26)

1. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 1795;2009:37-52.
2. Lee KH, Lee KB, Kim TY, Han SW, Oh DY, Im SA, et al. Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. BMC Cancer. 2015;15:721.
3. Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449-58.
4. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 2013;18:865-75.
5. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190-203.
6. Davies KD, Le AH, Astling DP, Skokan MC, Aisner DL, Berge EM, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18:4570-9.
7. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res. 2013;19:4040-5.
8. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-71.
9. Solomon B. Validating ROS1 Rearrangements as a therapeutic target in non-small-cell lung cancer. J Clin Oncol. 2015;33:1-3.
10. Jurmeister P, Lenze D, Berg E, Mende S, Schäper F, Kellner U, et al. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. Lung Cancer. 2015;87:122-9.
11. Shan L, Lian F, Guo L, Qiu T, Ling Y, Ying J, et al. Detection of ROS1 gene rearrangement in lung adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR. PLoS One. 2015;10:e0120422. doi: 10.1371/journal.pone.0120422.
12. Cai W, Li X, Su C, Fan L, Zheng L, Fei K, et al. ROS1 fusions in Chinese patients with non-small-cell lung cancer. Ann Oncol. 2013;24:1822-7.
13. Boyle TA, Masago K, Ellison KE, Yatabe Y, Hirsch FR. ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer. 2015;16:106-11.
14. Yoshida A, Tsuta K, Wakai S, Arai Y, Asamura H, Shibata T, et al. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol. 2014;27:711-20.
15. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243-60.
16. Travis W, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-85.
17. Sica G, Yoshizawa A, Sima CS, Azzoli CG, Downey RJ, Rusch VW, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010;34(8):1155-62.
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartzd LH, Sargente D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
19. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-5.
20. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT. ROS1 Rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863-70.
21. Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992-9. doi: 10.1200/JCO.2014.58.3302.
22. Warth A, Muley T, Dienemann H, Goeppert B, Stenzinger A, Schnabel P, et al. ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology. 2014;65:187-94.
23. Boyle TA, Masago K, Ellison KE, Yatabe Y, Hirsch FR. ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer. 2015;16(2):106-11.
24. Li C, Fang R, Sun Y, Han X, Li F, Gao B, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from east Asian never smokers. PLoS One. 2011;6:e28204. doi: 10.1371/journal.pone.0028204.
25. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3(1):S7-S19.
26. Gruver AM, Liu L, Vaillancourt P, et al. Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET). Histopathology. 2014;65(6):879-96.